Replimune Beats On A Shrinking Loss, But The TUDRIQEV Launch Is Still Measured In Accounts, Not Revenue

Replimune Group (NASDAQ: REPL) reported a fiscal second-quarter loss of $0.54 per share, beating the consensus estimate of a $0.70 loss by 22.9%. Earnings improved 40.0% year over year as the net loss narrowed to $57.1 million from $83.1 million. The company booked no revenue, because TUDRIQEV (formerly RP1) did not reach its first melanoma patients until October 6, after the quarter closed. The beat matters less than what comes next. This was the last pre-revenue quarter, and the investment case now depends on how quickly a $450,000-per-course oncolytic therapy converts formulary wins into recognized sales. Management chose not to quantify that yet.

The beat came from lower costs, not from the business. Research and development expense fell to $34.4 million from $57.9 million a year earlier and from $49.3 million in the prior quarter. The company cited lower personnel costs and reduced direct spending as the IGNYTE, ARTACUS and CERPASS studies wind down. SG&A of $21.9 million was below the $26.4 million reported a year ago but up from $19.0 million sequentially, the first sign of launch spending returning to the expense line. Below the operating line, the picture was less favorable:

• Interest expense on debt rose to $2.5 million from $1.5 million.
• Investment income roughly halved.
• Weighted shares climbed to 105.2 million from 91.9 million, which flatters the per-share comparison less than the loss reduction suggests.

Cash rose to $307.8 million, but only because of roughly $141 million in net proceeds from the August stock offering and a $15 million debt draw. The runway is now framed only as "greater than twelve months."

The conference call was far more confident than any prior Replimune call. Management described a "defining moment" and momentum that "continues to build each week." The early launch evidence supports that tone:

• More than 15 institutions prescribed within about 20 business days, and the number was closer to 20 by the time of the call.
• About 20 accounts have placed TUDRIQEV on formulary, including Moffitt and Memorial Sloan Kettering, and some sites are bypassing formulary review entirely.
• Management expects to roughly double initiating accounts by the end of calendar 2026.
• The company has engaged more than 70% of its 200 priority accounts.
• Community accounts outside that target list are adopting unprompted, and image-guided injections into deep lesions are already occurring.

Reimbursement moved unusually fast. TUDRIQEV earned an NCCN Category 2A listing, and commercial policies now cover a majority of commercial lives plus Medicare, with retreatment allowed and no volume caps. The broad label also helps, since it requires no prior BRAF therapy and permits injection into visceral lesions.

The quality of the launch disclosure deserves scrutiny, though. Management again offered no revenue guidance and will not disclose patient counts, even though it had earlier indicated patient numbers would eventually be provided. Revenue per patient will be recognized over several quarters, so reported sales will lag and may be lumpy. The product will remain on a miscellaneous J-code until a permanent code arrives, expected by April 2027. The commercial footprint also shrank:

• The team was "rebuilt" at 23 account managers, down from roughly 60 customer-facing staff before approval.
• The initial target list narrowed to 200 priority accounts from about 350, with a second wave of 250 to follow.
• The addressable U.S. population is now framed at about 10,000 patients, slightly below the earlier math.

Longer term, the approval is accelerated, so continued marketing depends on the IGNYTE-3 confirmatory trial, which uses an overall survival endpoint. RP2's REVEAL study in uveal melanoma is the next pipeline catalyst.

Investor sentiment improved materially, moving from essentially neutral at -0.0065 after the prior report to +0.28. That shift reflects the approval and launch rather than the earnings line. Price action has been more cautious. At $13.05 on the eve of the report, shares were down 14.1% from the $15.19 open after the August release and 20.1% below the 52-week high of $16.33 set on September 2. Shares remain about 42.7% above the 200-day moving average of $9.14 and have bounced 22.3% off the October 19 low of $10.67. The stock has been working through dilution and launch uncertainty, but that has not erased the longer-term rerating. Price trend readings are neutral, while AVWAP remains negative, consistent with a stock that has struggled to hold post-offering gains.

The bottom line is that Replimune delivered a clean, cost-driven beat, but that beat is now the least important number in the story. The early TUDRIQEV indicators are encouraging: account adoption, formulary placement, rapid payer coverage and unprompted community uptake. Yet bears have legitimate ammunition. There is no revenue guidance, no patient disclosure, a lean rebuilt salesforce, a runway framed at just over a year, and delayed revenue recognition. The next two quarters must translate account momentum into visible sales before the market fully credits the launch.

Read our earnings preview for Replimune Group, Inc.: https://www.earningswhispers.com/article/REPL/21308

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.